Aquestive Therapeutics第四季度GAAP每股收益$(0.19),逊于预期的$(0.14),销售额$1187万低于预期的$1308万

财报速递2025-03-06
Aquestive Therapeutics (NASDAQ:AQST) 报告季度每股亏损$(0.19),低于分析师普遍预期的$(0.14),差距为35.71%。相比去年同期的每股亏损$(0.10),这是一个90%的下降。公司报告季度销售额为$1187万,低于分析师普遍预期的$1308万,差距为9.30%。这一数据相较去年同期的销售额$1321万下降了10.14%。

以上内容来自Benzinga Earnings专栏,原文如下:

Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 90 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $11.87 million which missed the analyst consensus estimate of $13.08 million by 9.30 percent. This is a 10.14 percent decrease over sales of $13.21 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法